Table 1.
Patients’ and healthy donors’ characteristics
| ID | Gender | Age | Disease | Prior therapy | Disease status | Residual disease detected by RT‐PCR | |
|---|---|---|---|---|---|---|---|
| Patients | AML‐1 | F | 55 | AML without maturation | Chemotherapy, WT1 vaccination | 2nd CR | (High levels of WT1) |
| AML‐2 | F | 66 | AML with maturation | Chemotherapy | 1st CR | (High levels of WT1) | |
| AML‐3 | M | 64 | AML with t(8; 21)(q22; q22) | Chemotherapy | 2nd CR | (Positivity of AML1/ETO) | |
| AML‐4 | F | 45 | AML with t(15; 17)(q22; q12) | Chemotherapy | 2nd CR | (Positivity of PML/RARα) | |
| MDS‐1 | M | 62 | Secondary MDS, chronic myelomonocytic leukemia | Chemotherapy for prior AML | – | (High levels of WT1) | |
| MDS‐2 | M | 66 | MDS, refractory anemia with excess blasts‐2 | Best supportive care | – | (High levels of WT1) | |
| MDS‐3 | M | 69 | AML transformed from MDS | Chemotherapy | 1st CR | (High levels of WT1) | |
| MDS‐4 | M | 58 | MDS, refractory anemia with excess blasts‐2 | Best supportive care | – | (High levels of WT1) | |
| Healthy donors | HD‐1 | F | 23 | ||||
| HD‐2 | M | 24 | |||||
| HD‐3 | M | 30 | |||||
| HD‐4 | F | 25 | |||||
| HD‐5 | F | 26 |
AML, acute myeloid leukemia; CR, complete remission; ETO, eight twenty one; HD, healthy donor; MDS, myelodysplastic syndrome; PML, promyelocytic leukemia; RARα, retinoic acid receptor‐α; WT1, Wilms’ tumor gene 1.